GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Burzynski Research Institute Inc (OTCPK:BZYR) » Definitions » Research & Development

BZYR (Burzynski Research Institute) Research & Development : $1.06 Mil (TTM As of Nov. 2024)


View and export this data going back to . Start your Free Trial

What is Burzynski Research Institute Research & Development?

Research & Development is the aggregate amount of research and development expenses during the year. Burzynski Research Institute's Research & Development for the three months ended in Nov. 2024 was $0.30 Mil. Its Research & Development for the trailing twelve months (TTM) ended in Nov. 2024 was $1.06 Mil.


Burzynski Research Institute Research & Development Historical Data

The historical data trend for Burzynski Research Institute's Research & Development can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Burzynski Research Institute Research & Development Chart

Burzynski Research Institute Annual Data
Trend Feb15 Feb16 Feb17 Feb18 Feb19 Feb20 Feb21 Feb22 Feb23 Feb24
Research & Development
Get a 7-Day Free Trial Premium Member Only Premium Member Only 1.20 1.02 0.76 0.72 0.87

Burzynski Research Institute Quarterly Data
Feb20 May20 Aug20 Nov20 Feb21 May21 Aug21 Nov21 Feb22 May22 Aug22 Nov22 Feb23 May23 Aug23 Nov23 Feb24 May24 Aug24 Nov24
Research & Development Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 0.22 0.25 0.23 0.28 0.30

Burzynski Research Institute Research & Development Calculation

This is the expense the company spent on research and development.

Research & Development for the trailing twelve months (TTM) ended in Nov. 2024 adds up the quarterly data reported by the company within the most recent 12 months, which was $1.06 Mil.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.


Burzynski Research Institute  (OTCPK:BZYR) Research & Development Explanation

If competitive advantage is created by a patent or tech advantage, at some point it will disappear.

High R&D usually dictates high SG&A which threatens the competitive advantage.


Burzynski Research Institute Research & Development Related Terms

Thank you for viewing the detailed overview of Burzynski Research Institute's Research & Development provided by GuruFocus.com. Please click on the following links to see related term pages.


Burzynski Research Institute Business Description

Traded in Other Exchanges
N/A
Address
9432 Katy Freeway, Houston, TX, USA, 77055
Burzynski Research Institute Inc operates primarily as a research and development facility of Antineoplaston drugs currently being tested for the use in the treatment of cancer, and provides consulting services.
Executives
Monika Szopa-paszkowiak director 9432 KATY FWY #200, HOUSTON TX 77055
Frederick Richard Schiff director 9432 KATY FREEWAY, HOUSTON TX 77055
Barbara Burzynski director, 10 percent owner 9432 KATY FREEWAY, HOUSTON TX 77055
Carlton Hazlewood director 9432 KATY FREEWAY, HOUSTON TX 77055
Patryk Goscianski officer: Secretary and Treasurer 9432 KATY FREEWAY, HOUSTON TX 77055
Gregory Burzynski director 9432 KATY FREEWAY, HOUSTON TX 77055
Tomasz Janicki officer: VP of Clinical Trials 9432 KATY FREEWAY, HOUSTON TX 77055
Michael Driscoll director 9432 KATY FREEWAY, HOUSTON TX 77055
Stanislaw Burzynski director, 10 percent owner, officer: President 9432 KATY FREEWAY, HOUSTON TX 77055
Dudley Reece Anderson officer: Chief Financial Officer 9432 OLD KATY RD., SUITE 200, HOUSTON TX 77055

Burzynski Research Institute Headlines

No Headlines